Lab research suggests more women could benefit from Herceptin
26. 02. 2013 | Cancer Research UKHerceptin may be effective against more types of breast cancer than previously thought, according to US research [1].
Image credit: Fvasconcellos 02:36, 28 May 2007 (UTC) - From PDB entry 1N8Z. More information: Cho HS, Mason K, Ramyar KX, et al. (2003). "Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab". Nature 421 (6924): 756–60. PMID 12610629. doi:10.1038/nature01392. Public Domain, Link
Herceptin, also known as trastuzumab, is often given to women with breast cancers that test positive for high levels of a protein known as HER2.
But HER2 could help fuel the growth of some breast cancers that are labelled HER2-negative, researchers at the University of Michigan Comprehensive Cancer Center discovered.
Read the whole article at Cancer Research UK
Reference
- Ithimakin, S., Day, K. C. et al. (2013). HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab Cancer Research DOI: 10.1158/0008-5472.CAN-12-3349
klíčová slova: Herceptin, trastuzumab, breast cancer, HER2-positive breast cancer, HER2-negative breast cancer, adjuvant therapy
